Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.45) EPS and FY2023 earnings at ($0.42) EPS.
Separately, StockNews.com started coverage on Aptose Biosciences in a report on Monday. They issued a “hold” rating on the stock.
Aptose Biosciences Price Performance
NASDAQ:APTO opened at $0.61 on Wednesday. The company has a market cap of $55.83 million, a P/E ratio of -0.96 and a beta of 1.48. The stock’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.96. Aptose Biosciences has a 1 year low of $0.58 and a 1 year high of $2.78.
Hedge Funds Weigh In On Aptose Biosciences
Institutional investors have recently modified their holdings of the company. Formidable Asset Management LLC bought a new position in shares of Aptose Biosciences during the 1st quarter valued at about $122,000. Annandale Capital LLC bought a new position in shares of Aptose Biosciences during the 1st quarter valued at about $272,000. Toronto Dominion Bank increased its position in shares of Aptose Biosciences by 76.6% during the 1st quarter. Toronto Dominion Bank now owns 50,186 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 21,776 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Aptose Biosciences during the 1st quarter valued at about $27,000. Finally, Voss Capital LLC increased its position in shares of Aptose Biosciences by 27.3% during the 2nd quarter. Voss Capital LLC now owns 700,010 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 150,010 shares during the last quarter. 27.16% of the stock is currently owned by institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- Get a free copy of the StockNews.com research report on Aptose Biosciences (APTO)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.